agilon health vs Concentra Group Holdings Parent
AGL and CON side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGL and CON compare
Concentra Group Holdings Parent is the larger company, worth 3.0 times as much as agilon health ($5.5B against $1.9B).
Concentra Group Holdings Parent grew revenue faster over the last twelve months (11.8% versus 2.0% for agilon health).
Concentra Group Holdings Parent keeps more of each dollar of sales as profit, with a net margin of 9.3% compared with −1.5% at agilon health.
Concentra Group Holdings Parent pays a dividend yielding 0.59%; agilon health does not pay one.
Concentra Group Holdings Parent scores higher on the StockData Score (12 against 4 for agilon health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGL | CON |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $5.5B |
| Share price | $110.30 | $42.99 |
| Change, 1 year | 613% | 120% |
| Change, 5 years | −81.4% | – |
| Beta (5Y) | 1.26 | 0.50 |
| Employees | 856 | 13K |
| StockData Score | ||
| Total score | 4 | 12 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 25.6× |
| P/S | 0.3× (better) | 2.3× |
| P/B | – | 10.8× |
| EV/EBITDA | – | 14.6× |
| P/FCF | – | 21.3× |
| FCF yield | −0.92% | 4.7% (better) |
| Fair value | – | $35.63 |
| Margin of safety | – | −20.7% |
| Growth | ||
| Revenue growth (TTM) | 2.0% | 11.8% (better) |
| Revenue growth, 5Y average | 37.2% | – |
| Net income growth (TTM) | – | 41.2% |
| EPS growth (TTM) | – | 40.0% |
| Profitability | ||
| Gross margin | – | 29.9% |
| Operating margin | −2.6% | 16.9% (better) |
| Net margin | −1.5% | 9.3% (better) |
| FCF margin | −0.28% | 11.0% (better) |
| Return on equity | – | 48.5% |
| Return on invested capital | – | 15.6% |
| Financial health | ||
| Debt / equity | – | 3.00 |
| Net debt / EBITDA | – | 3.02 |
| Interest coverage | −22.4× | – |
| Current ratio | 1.13 | 1.30 (better) |
| Altman Z-score | 2.83 (better) | 2.72 |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.59% |
| Payout ratio | – | 14.8% |
| Years of dividend growth | – | 1 |
| Buyback yield | – | 1.5% |
| Shareholder yield | 0.00% | 2.1% (better) |
| Ownership | ||
| Held by institutions | 95.8% | 88.2% |
| Held by insiders | 10.1% | 11.3% |
| Insider net buying, 12 months | $300K (better) | −$14.6M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 5.6% | 2.0% |
Go deeper
- AGL stock overview
- AGL income statement
- AGL valuation and score
- CON stock overview
- CON income statement
- CON valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.